Marimed Inc banner

Marimed Inc
OTC:MRMD

Watchlist Manager
Marimed Inc Logo
Marimed Inc
OTC:MRMD
Watchlist
Price: 0.087 USD -3.33% Market Closed
Market Cap: $34.4m

Marimed Inc
Investor Relations

MariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. The company is headquartered in Newton, Massachusetts and currently employs 260 full-time employees. The company went IPO on 2012-05-04. The firm develops, operates, manages, and optimizes facilities for the cultivation, production and dispensing of medicinal and recreational cannabis. The firm also licenses its brands of cannabis and hemp-infused products, along with other brands in domestic markets and overseas. The firm also provides its clients with ongoing regulatory, accounting, real estate, human resources, and administrative services. The company has its own brands of cannabis flower, concentrates, and precision-dosed products utilizing strains and formulations. The company markets its cannabis flowers and concentrates under the Nature’s Heritage brand; cannabis-infused chewable tables and powder drink mixes under the brand names Kalm Fusion and K Fusion; all natural fruit chews under the Betty’s Eddies brand; and brownies, cookies, and other social sweets under the Bubby’s Baked brand.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Revenue Growth: MariMed reported Q3 2025 consolidated revenue of $40.8 million, up 3% sequentially and 4% year-over-year.

Wholesale Strength: Wholesale revenue grew 5% quarter-over-quarter and now represents 44% of product revenue as the company shifts focus from retail to wholesale.

Margin Pressure: Gross margin declined to 41.4%, down 400 bps sequentially, impacted by aggressive discounting and changes in loyalty program accounting.

Positive Cash Flow: The company generated $2.7 million in cash flow from operations, up from $297,000 in Q2.

Delaware Outperformance: Retail revenue in Delaware grew nearly 48% sequentially due to the adult-use launch and strong brand activation.

Strategic Market Moves: MariMed exited Missouri to focus on more profitable markets and expanded licensing partnerships into Pennsylvania, New York, and Maine.

Hemp Expansion: MariMed is entering the hemp-based THC beverage market with new product launches planned for early 2026.

Key Financials
Revenue
$40.8 million
Adjusted Gross Margin
41.4%
Net Loss
$2.9 million
Operating Expenses
$14.8 million
Adjusted EBITDA
$5.1 million
Cash and Cash Equivalents
$6.6 million
Operating Working Capital
$38.2 million
Cash Flow from Operations
$2.7 million
Wholesale as % of Product Revenue
44%
Earnings Call Recording
Other Earnings Calls

Management

Mr. Jon R. Levine
Co-Founder, CEO, President, Secretary, Treasurer & Director
No Bio Available
Mr. Timothy Shaw
Chief Operating Officer
No Bio Available
Mr. Mario Pinho
Chief Financial Officer
No Bio Available
Mr. Jonathan W. Rider
Chief Information Officer
No Bio Available
Mr. Steve Wayne West
Vice President of Investor Relations
No Bio Available
Mr. Howard Schacter
Chief Communications Officer
No Bio Available
Ms. Sara Gullickson
Vice President of Marketing
No Bio Available
Mr. Ryan Crandall
Chief Revenue Officer
No Bio Available
Mr. Charles Holt Finnie
Chief Strategy Officer
No Bio Available

Contacts

Address
MASSACHUSETTS
Newton
26 Ossipee Rd, Suite 201
Contacts
+16177955140.0
ir.marimedinc.com